MedPath

Importance of special blood test in obese patients receiving blood thinner enoxaparin, posted for laparoscopic bariatric surgery

Not Applicable
Conditions
Health Condition 1: null- Morbidly obese patients(BMI more than 40Kg/m2 or BMI more than 35Kg/M2 with an obesity related co-morbidty), posted for laparoscopic bariatric surgery
Registration Number
CTRI/2017/08/009476
Lead Sponsor
arani KK
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

Patients with morbid obesity (BMI more than 40 Kg/m2 or BMI more than 35 Kg/m2 with an obesity related co-morbidity), undergoing laparoscopic bariatric surgery

Exclusion Criteria

1. Patients on anticoagulants or antiplatelet drugs

2. Patients with h/o DVT and PE

3. Chronic liver disease (serum bilirubin above 2mg/dl)

4. Chronic renal disease (Cr Cl less than 30ml/min)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Anti-Xa levels - 2.7 ml of blood collected in Vacutainers (BD Franklin Lakes, NJ, USA), containing Buff. Na citrate, 0.109 M, 3.2%,to monitor anti-Xa levels <br/ ><br>Timepoint: Anti-Xa levels <br/ ><br>1. On the day of surgery, before starting operation at 8 AM (12 hrs after 1st dose of enoxaparin) <br/ ><br>2. 4 hrs after after the dose of enoxaparin, administered 8 hrs after surgery <br/ ><br>3. 2nd postoperative day, 4 hrs after the dose of enoxaparin <br/ ><br>4. 8th postoperative day, 4 hrs after the dose of enoxaparin <br/ ><br>5.15th postoperative day, 4 hrs after the dose of enoxaparin <br/ ><br>6. 30th postoperative day, 4 hrs after the dose of enoxaparin <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
ltrasound clour Doppler mapping of leg veins to rule out presence of any asymptomatic DVTTimepoint: Preoperatve, on 8th and 30th postoperative days
© Copyright 2025. All Rights Reserved by MedPath